Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study
Sponsor: Tanta University
Summary
1. Primary Aim: To evaluate the efficacy of atomoxetine in reducing the frequency of primary nocturnal enuresis episodes in children with ADHD. 2. Secondary Aim: To determine if improvements in attention symptoms correlate with reductions in nocturnal enuresis episodes.
Official title: Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD
Key Details
Gender
All
Age Range
6 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-02-28
Completion Date
2025-09-05
Last Updated
2025-02-27
Healthy Volunteers
Yes
Conditions
Interventions
Atomoxetine
Atomoxetine, 0.5-1.2 mg/kg/day, administered in the evening for six months.
Placebo
Placebo identical in form and dosing schedule for six months.